DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Colistimethate (Colistimethate Sodium) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

INTRAVENOUS ADMINISTRATION

1.  Direct Intermittent Administration - Slowly inject one-half of the total daily dose  over a period of 3 to 5 minutes every 12 hours.

2.  Continuous Infusion - Slowly inject one-half of the total daily dose over 3 to 5 minutes. Add the remaining half of the total daily dose of Colistimethate for Injection to one of the following:

0.9% NaCl

5% dextrose in 0.9% NaCl

5% dextrose in water

5% dextrose in 0.45% NaCl

5% dextrose in 0.225% NaCl

Lactated Ringer’s solution

10% invert sugar solution

There is not sufficient data to recommend usage of Colistimethate for Injection with other drugs, or other than the above listed infusion solutions.

Administer the second half of the total daily dose by slow intravenous infusion, starting 1 to 2 hours after the initial dose, over the next 22 to 23 hours. In the presence of impaired renal function, reduce the infusion rate depending on the degree of renal impairment.

The choice of intravenous solution and the volume to be employed are dictated by the requirements of fluid and electrolyte management.

Any infusion solution containing colistimethate sodium should be freshly prepared and used for no longer than 24 hours.

 

COLISTIMETHATE SUMMARY

Colistimethate for Injection USP is a sterile parenteral antibiotic product which, when reconstituted (see Reconstitution), is suitable for intramuscular or intravenous administration. Each vial contains colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity).

Colistimethate for Injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. This antibiotic is not indicated for infections due to Proteus or Neisseria. Colistimethate for Injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Colistimethate for Injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection and other antibacterial drugs, Colistimethate for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.


See all Colistimethate indications & dosage >>

COLISTIMETHATE NEWS HIGHLIGHTS

Media Articles Related to Colistimethate

Probiotic Mouthwash May Prevent Ventilator-Associated Pneumonia
Source: MedPage Today Emergency Medicine [2008.11.05]

Interstitial Pneumonia
Source: MedicineNet Pulmonary Fibrosis Specialty [2008.11.04]

Health Tip: Treating Pneumonia
Source: MedicineNet Aches, Pain, Fever Specialty [2008.10.31]

Coconut Oil May Help Fight Childhood Pneumonia
Source: MedicineNet Aches, Pain, Fever Specialty [2008.10.31]

Pneumonia Death Less Likely In Statin Users
Source: Cholesterol News From Medical News Today [2008.10.29]

more >>

Page last updated: 2008-11-05

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008